For decades, the war on drugs has raged its way across the world, taking a particularly strong hold in America. With politicians from Reagan to Biden fathering policies that have incarcerated millions and killed many more, the world is beginning to see the disastrous effects of drug prohibition. For one thing, it actually can increase deaths from drug overdoses; when Portugal decriminalized all drugs, their addiction and overdose rates plummeted. But another drug, ketamine, offers solutions to the opioid crisis and many other medical problems.
Could the iPhone have been born from the depths of an LSD trip? Steve Jobs tripped on acid a lot in college. It very well could be possible. But pairing drugs with any sort of productivity often receives pushback. Open up a little bit, and let your conceptions be shaken. It may very well be the case that many modern silicon valley innovations may be coming from psychedelic microdosing.
The FDA just approved a new antidepressant, the first of its kind. Unlike other antidepressants, this one is a nasal spray. Esketamine, under the brand name Spravato, is developed by Johnson & Johnson and has been in testing for the past 2 years. The drug has seen remarkable success. This success is interesting because the drug is closely tied to the club drug “Special K.” Related to MDMA, Special K is known as Ecstasy. This marks the first major breakthrough in the treatment of depression since the 1980s.